FindTrial
Sign In

rescue therapy

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, First Affiliated Hospital Xi'an Jiaotong University, National Cheng-Kung University Hospital

Conditions

Breast CancerCardiotoxicityChemotherapeutic ToxicityChemotherapy-Induced Nausea and Vomiting (CINV)Heart FailureHepatitis B, ChronicLymphomaVirus Diseases

Phase 3

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
CompletedNCT01594749
Merck Sharp & Dohme LLCChemotherapy-Induced Nausea and Vomiting (CINV)
Start: 2012-09-24End: 2014-11-03Updated: 2018-09-04

Unknown Phase

Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory
NCT05376124
First Affiliated Hospital Xi'an Jiaotong UniversityHepatitis B, Chronic, Virus Diseases
Start: 2022-01-01End: 2025-12-31Target: 110Updated: 2023-02-03
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
NCT05892146
National Cheng-Kung University HospitalBreast Cancer, Cardiotoxicity, Chemotherapeutic Toxicity +2
Start: 2021-05-05End: 2025-12-31Target: 100Updated: 2023-06-07

Related Papers

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type
BMC Cancer2020-09-259 citations
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
2018-05-288 citations
Abstract P6-11-11: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer receiving moderately emetogenic chemotherapy regimens
Cancer Research2018-02-152 citations
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based therapies.
Journal of Clinical Oncology2017-05-20
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
2015-10-0855 citations
A phase III, randomized, double-blind study of single-dose intravenous fosaprepitant in preventing chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.
Journal of Clinical Oncology2015-05-203 citations
Phase III design for a trial of single-dose fosaprepitant (FA) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).
Journal of Clinical Oncology2014-05-20